Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer

NCT02797964 is registered in ClinicalTrials.gov with Sierra Oncology LLC - a GSK company as lead sponsor.

NCT NCT02797964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02797964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
Lead sponsor
Sierra Oncology LLC - a GSK company
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2016
Completion date
October 28, 2019
Enrollment
107 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors or non-hodgkin's lymphoma (nhl)